Drugs / resecabtagene autoleucel
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT07006805 | Jun 2026 → Sep 2028 | relapsing-remitting multiple sclerosis | Cabaletta Bio | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT06359041 | Dec 2024 → Sep 2029 expected | generalized myasthenia gravis | Cabaletta Bio | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06328777 | Jul 2024 → Jul 2029 expected | systemic sclerosis | Cabaletta Bio | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06121297 | Feb 2024 → Dec 2029 expected | lupus nephritis, systemic lupus erythematosus | Cabaletta Bio | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04422912 | Sep 2020 → Jan 2029 expected | pemphigus vulgaris | Cabaletta Bio | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06154252 | Dec 2023 → Jul 2028 expected | antisynthetase syndrome, immune-mediated necrotizing myopathy, juvenile dermatomyositis, juvenile polymyositis | Cabaletta Bio | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | resecabtagene autoleucel | “The second part is a sub-study is being conducted to investigate if CABA-201, also called resecabtagene autoleucel, or "rese-cel", can be safely administered while achieving...” NCT04422912 ↗1“This study is being conducted to evaluate the safety and efficacy of an investigational cell therapy, CABA-201, also called resecabtagene autoleucel, or "rese-cel".” NCT06121297 ↗ |
| Known as | CABA-201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06154252 ↗ |
| Known as | rese-cel | “The second part is a sub-study is being conducted to investigate if CABA-201, also called resecabtagene autoleucel, or "rese-cel", can be safely administered while achieving...” NCT04422912 ↗1“This study is being conducted to evaluate the safety and efficacy of an investigational cell therapy, CABA-201, also called resecabtagene autoleucel, or "rese-cel".” NCT06121297 ↗ |
| Known as | Resecabtagen autoleucel | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068289 ↗ |
| Modality | Cell therapy | “CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]” NCT04422912 ↗ |
| Route | Intravenous | “Single intravenous infusion of CABA-201 at escalating doses” NCT04422912 ↗ |
| Target | CD19 | “CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]” NCT04422912 ↗ |